Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Tolulope T. Sajobi is active.

Publication


Featured researches published by Tolulope T. Sajobi.


Circulation | 2016

Analysis of Workflow and Time to Treatment on Thrombectomy Outcome in the Endovascular Treatment for Small Core and Proximal Occlusion Ischemic Stroke (ESCAPE) Randomized, Controlled Trial

Bijoy K. Menon; Tolulope T. Sajobi; Yukun Zhang; Jeremy Rempel; Ashfaq Shuaib; John Thornton; David Williams; Daniel Roy; Alexandre Y. Poppe; Tudor G. Jovin; Biggya Sapkota; Blaise W. Baxter; Timo Krings; Frank L. Silver; Donald Frei; Christopher Fanale; Donatella Tampieri; Jeanne Teitelbaum; Cheemun Lum; Dar Dowlatshahi; Muneer Eesa; Mark Lowerison; Noreen Kamal; Andrew M. Demchuk; Michael D. Hill; Mayank Goyal

Background— The Endovascular Treatment for Small Core and Proximal Occlusion Ischemic Stroke (ESCAPE) trial used innovative imaging and aggressive target time metrics to demonstrate the benefit of endovascular treatment in patients with acute ischemic stroke. We analyze the impact of time on clinical outcome and the effect of patient, hospital, and health system characteristics on workflow within the trial. Methods and Results— Relationship between outcome (modified Rankin Scale) and interval times was modeled by using logistic regression. Association between time intervals (stroke onset to arrival in endovascular-capable hospital, to qualifying computed tomography, to groin puncture, and to reperfusion) and patient, hospital, and health system characteristics were modeled by using negative binomial regression. Every 30-minute increase in computed tomography-to-reperfusion time reduced the probability of achieving a functionally independent outcome (90-day modified Rankin Scale 0–2) by 8.3% (P=0.006). Symptom onset-to-imaging time was not associated with outcome (P>0.05). Onset-to-endovascular hospital arrival time was 42% (34 minutes) longer among patients receiving intravenous alteplase at the referring hospital (drip and ship) versus direct transfer (mothership). Computed tomography-to-groin puncture time was 15% (8 minutes) shorter among patients presenting during work hours versus off hours, 41% (24 minutes) shorter in drip-ship patients versus mothership, and 43% (22 minutes) longer when general anesthesia was administered. The use of a balloon guide catheter during endovascular procedures shortened puncture-to-reperfusion time by 21% (8 minutes). Conclusions— Imaging-to-reperfusion time is a significant predictor of outcome in the ESCAPE trial. Inefficiencies in triaging, off-hour presentation, intravenous alteplase administration, use of general anesthesia, and endovascular techniques offer major opportunities for improvement in workflow. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT01778335.


International Journal of Stroke | 2015

Endovascular treatment for Small Core and Anterior circulation Proximal occlusion with Emphasis on minimizing CT to recanalization times (ESCAPE) trial: methodology.

Andrew M. Demchuk; Mayank Goyal; Bijoy K. Menon; Muneer Eesa; Karla J. Ryckborst; Noreen Kamal; Shivanand Patil; Sachin Mishra; Mohammed A. Almekhlafi; Privia A. Randhawa; Daniel Roy; Robert Willinsky; Walter Montanera; Frank L. Silver; Ashfaq Shuaib; Jeremy Rempel; Tudor G. Jovin; Donald Frei; Biggya Sapkota; J. Michael Thornton; Alexandre Y. Poppe; Donatella Tampieri; Cheemun Lum; Alain Weill; Tolulope T. Sajobi; Michael D. Hill

ESCAPE is a prospective, multicenter, randomized clinical trial that will enroll subjects with the following main inclusion criteria: less than 12 h from symptom onset, age > 18, baseline NIHSS >5, ASPECTS score of >5 and CTA evidence of carotid T/L or M1 segment MCA occlusion, and at least moderate collaterals by CTA. The trial will determine if endovascular treatment will result in higher rates of favorable outcome compared with standard medical therapy alone. Patient populations that are eligible include those receiving IV tPA, tPA ineligible and unwitnessed onset or wake up strokes with 12 h of last seen normal. The primary end-point, based on intention-to-treat criteria is the distribution of modified Rankin Scale scores at 90 days assessed using a proportional odds model. The projected maximum sample size is 500 subjects. Randomization is stratified under a minimization process using age, gender, baseline NIHSS, baseline ASPECTS (8–10 vs. 6–7), IV tPA treatment and occlusion location (ICA vs. MCA) as covariates. The study will have one formal interim analysis after 300 subjects have been accrued. Secondary end-points at 90 days include the following: mRS 0–1; mRS 0–2; Barthel 95–100, EuroQOL and a cognitive battery. Safety outcomes are symptomatic ICH, major bleeding, contrast nephropathy, total radiation dose, malignant MCA infarction, hemicraniectomy and mortality at 90 days.


American Journal of Neuroradiology | 2014

Early Reperfusion Rates with IV tPA Are Determined by CTA Clot Characteristics

Sachin Mishra; J. Dykeman; Tolulope T. Sajobi; A. Trivedi; Mohammed A. Almekhlafi; Sung-Il Sohn; S. Bal; Emmad Qazi; Ana Calleja; Muneer Eesa; Mayank Goyal; Andrew M. Demchuk; Bijoy K. Menon

These authors evaluated CTA studies of 228 patients paying special attention to the clot features, and correlated these features with early reperfusion rates. Clot features that predicted successful early reperfusion included: shorter clot, residual flow within the clot, and distal location. Reperfusion was achieved in only 8% of patients with longer and proximal clots and in those without residual flow. BACKGROUND AND PURPOSE: An ability to predict early reperfusion with IV tPA in patients with acute ischemic stroke and intracranial clots can help clinicians decide if additional intra-arterial therapy is needed or not. We explored the association between novel clot characteristics on baseline CTA and early reperfusion with IV tPA in patients with acute ischemic stroke by using classification and regression tree analysis. MATERIALS AND METHODS: Data are from patients with acute ischemic stroke and proximal anterior circulation occlusions from the Calgary CTA data base (2003–2012) and the Keimyung Stroke Registry (2005–2009). Patients receiving IV tPA followed by intra-arterial therapy were included. Clot location, length, residual flow within the clot, ratio of contrast Hounsfield units pre- and postclot, and the M1 segment origin to the proximal clot interface distance were assessed on baseline CTA. Early reperfusion (TICI 2a and above) with IV tPA was assessed on the first angiogram. RESULTS: Two hundred twenty-eight patients (50.4% men; median age, 69 years; median baseline NIHSS score, 17) fulfilled the inclusion criteria. Median symptom onset to IV tPA time was 120 minutes (interquartile range = 70 minutes); median IV tPA to first angiography time was 70.5 minutes (interquartile range = 62 minutes). Patients with residual flow within the clot were 5 times more likely to reperfuse than those without it. Patients with residual flow and a shorter clot length (≤15 mm) were most likely to reperfuse (70.6%). Patients with clots in the M1 MCA without residual flow reperfused more if clots were distal and had a clot interface ratio in Hounsfield units of <2 (36.8%). Patients with proximal M1 clots without residual flow reperfused 8% of the time. Carotid-T/-L occlusions rarely reperfused (1.7%). Interrater reliability for these clot characteristics was good. CONCLUSIONS: Our study shows that clot characteristics on CTA help physicians estimate a range of early reperfusion rates with IV tPA.


BMC Cancer | 2013

Metabolic system alterations in pancreatic cancer patient serum: potential for early detection

Shawn Ritchie; Hirofumi Akita; Ichiro Takemasa; Hidetoshi Eguchi; Elodie Pastural; Hiroaki Nagano; Morito Monden; Yuichiro Doki; Masaki Mori; Wei Jin; Tolulope T. Sajobi; Dushmanthi Jayasinghe; Bassirou Chitou; Yasuyo Yamazaki; Thayer White; Dayan B. Goodenowe

BackgroundThe prognosis of pancreatic cancer (PC) is one of the poorest among all cancers, due largely to the lack of methods for screening and early detection. New biomarkers for identifying high-risk or early-stage subjects could significantly impact PC mortality. The goal of this study was to find metabolic biomarkers associated with PC by using a comprehensive metabolomics technology to compare serum profiles of PC patients to healthy control subjects.MethodsA non-targeted metabolomics approach based on high-resolution, flow-injection Fourier transform ion cyclotron resonance mass spectrometry (FI-FTICR-MS) was used to generate comprehensive metabolomic profiles containing 2478 accurate mass measurements from the serum of Japanese PC patients (n=40) and disease-free subjects (n=50). Targeted flow-injection tandem mass spectrometry (FI-MS/MS) assays for specific metabolic systems were developed and used to validate the FI-FTICR-MS results. A FI-MS/MS assay for the most discriminating metabolite discovered by FI-FTICR-MS (PC-594) was further validated in two USA Caucasian populations; one comprised 14 PCs, six intraductal papillary mucinous neoplasims (IPMN) and 40 controls, and a second comprised 1000 reference subjects aged 30 to 80, which was used to create a distribution of PC-594 levels among the general population.ResultsFI-FTICR-MS metabolomic analysis showed significant reductions in the serum levels of metabolites belonging to five systems in PC patients compared to controls (all p<0.000025). The metabolic systems included 36-carbon ultra long-chain fatty acids, multiple choline-related systems including phosphatidylcholines, lysophosphatidylcholines and sphingomyelins, as well as vinyl ether-containing plasmalogen ethanolamines. ROC-AUCs based on FI-MS/MS of selected markers from each system ranged between 0.93 ±0.03 and 0.97 ±0.02. No significant correlations between any of the systems and disease-stage, gender, or treatment were observed. Biomarker PC-594 (an ultra long-chain fatty acid), was further validated using an independently-collected US Caucasian population (blinded analysis, n=60, p=9.9E-14, AUC=0.97 ±0.02). PC-594 levels across 1000 reference subjects showed an inverse correlation with age, resulting in a drop in the AUC from 0.99 ±0.01 to 0.90 ±0.02 for subjects aged 30 to 80, respectively. A PC-594 test positivity rate of 5.0% in low-risk reference subjects resulted in a PC sensitivity of 87% and a significant improvement in net clinical benefit based on decision curve analysis.ConclusionsThe serum metabolome of PC patients is significantly altered. The utility of serum metabolite biomarkers, particularly PC-594, for identifying subjects with elevated risk of PC should be further investigated.


Stroke | 2015

Time-Dependent Computed Tomographic Perfusion Thresholds for Patients With Acute Ischemic Stroke

Christopher D. d’Esterre; Mari E. Boesen; Seong Hwan Ahn; Pooneh Pordeli; Mohamed Najm; Priyanka Minhas; Paniz Davari; Enrico Fainardi; Marta Rubiera; Alexander V. Khaw; Andrea Zini; Richard Frayne; Michael D. Hill; Andrew M. Demchuk; Tolulope T. Sajobi; Nils Daniel Forkert; Mayank Goyal; Ting Y. Lee; Bijoy K. Menon

Background and Purpose— Among patients with acute ischemic stroke, we determine computed tomographic perfusion (CTP) thresholds associated with follow-up infarction at different stroke onset-to-CTP and CTP-to-reperfusion times. Methods— Acute ischemic stroke patients with occlusion on computed tomographic angiography were acutely imaged with CTP. Noncontrast computed tomography and magnectic resonance diffusion–weighted imaging between 24 and 48 hours were used to delineate follow-up infarction. Reperfusion was assessed on conventional angiogram or 4-hour repeat computed tomographic angiography. Tmax, cerebral blood flow, and cerebral blood volume derived from delay-insensitive CTP postprocessing were analyzed using receiver–operator characteristic curves to derive optimal thresholds for combined patient data (pooled analysis) and individual patients (patient-level analysis) based on time from stroke onset-to-CTP and CTP-to-reperfusion. One-way ANOVA and locally weighted scatterplot smoothing regression was used to test whether the derived optimal CTP thresholds were different by time. Results— One hundred and thirty-two patients were included. Tmax thresholds of >16.2 and >15.8 s and absolute cerebral blood flow thresholds of <8.9 and <7.4 mL·min−1·100 g−1 were associated with infarct if reperfused <90 min from CTP with onset <180 min. The discriminative ability of cerebral blood volume was modest. No statistically significant relationship was noted between stroke onset-to-CTP time and the optimal CTP thresholds for all parameters based on discrete or continuous time analysis (P>0.05). A statistically significant relationship existed between CTP-to-reperfusion time and the optimal thresholds for cerebral blood flow (P<0.001; r=0.59 and 0.77 for gray and white matter, respectively) and Tmax (P<0.001; r=−0.68 and −0.60 for gray and white matter, respectively) parameters. Conclusions— Optimal CTP thresholds associated with follow-up infarction depend on time from imaging to reperfusion.


Journal of Bone and Mineral Research | 2016

Sex‐ and Site‐Specific Normative Data Curves for HR‐pQCT

Lauren A. Burt; Zhiying Liang; Tolulope T. Sajobi; David A. Hanley; Steven K. Boyd

The purpose of this study was to develop age‐, site‐, and sex‐specific centile curves for common high‐resolution peripheral quantitative computed tomography (HR‐pQCT) and finite‐element (FE) parameters for males and females older than 16 years. Participants (n = 866) from the Calgary cohort of the Canadian Multicentre Osteoporosis Study (CaMos) between the ages of 16 and 98 years were included in this study. Participants’ nondominant radius and left tibia were scanned using HR‐pQCT. Standard and automated segmentation methods were performed and FE analysis estimated apparent bone strength. Centile curves were generated for males and females at the tibia and radius using the generalized additive models for location, scale, and shape (GAMLSS) package in R. After GAMLSS analysis, age‐, sex‐, and site‐specific centiles (10th, 25th, 50th, 75th, 90th) for total bone mineral density and trabecular number as well as failure load have been calculated. Clinicians and researchers can use these reference curves as a tool to assess bone health and changes in bone quality.


Quality of Life Research | 2013

Guidelines for secondary analysis in search of response shift

Carolyn E. Schwartz; Sara Ahmed; Richard Sawatzky; Tolulope T. Sajobi; Nancy E. Mayo; Joel S. Finkelstein; Lisa M. Lix; Mathilde G. E. Verdam; Frans J. Oort; Mirjam A. G. Sprangers

ObjectiveResponse shift methods have developed substantially in the past decade, with a notable emphasis on model-based methods for response shift detection that are appropriate for the analysis of existing data sets. These secondary data analyses have yielded useful insights and motivated the continued growth of response shift methods. However, there are also challenges inherent to the successful use of secondary analysis for response shift detection. Based on our experience with a number of secondary analyses, we propose guidelines for the optimal implementation of secondary analysis for detecting response shift.MethodsWe review the definition of response shift and recent advances in response shift theory. We describe current statistical methods that have been developed for or applied to response shift detection. We then discuss lessons learned when using these methods to test specific hypotheses about response shift in existing data and of the features of a data set that could guide early decision-making about undertaking a secondary analysis.ResultsA checklist is provided that includes guidelines for secondary analyses focusing on: (1) selecting an appropriate data set to investigate response shift; (2) prerequisites of data sets and their preparation for analysis; (3) managing missing data; (4) confirming that the data fit the requirements and assumptions of the selected response shift detection technique; (5) model fit evaluation; (6) interpreting results/response shift effect sizes; and (7) comparing findings across methods.ConclusionsThe guidelines-checklist has the potential to stimulate rigorous and replicable research using existing data sets and to assist investigators in assessing the appropriateness and potential of a data set and model-based methods for response shift research.


Journal of Clinical Epidemiology | 2016

Registry-based randomized controlled trials- what are the advantages, challenges, and areas for future research?

Guowei Li; Tolulope T. Sajobi; Bijoy K. Menon; Lawrence Korngut; Mark Lowerison; Matthew T. James; Stephen B. Wilton; Tyler Williamson; Stephanie J. Gill; Lauren L. Drogos; Eric E. Smith; Sunita Vohra; Michael D. Hill; Lehana Thabane

Registry-based randomized controlled trials are defined as pragmatic trials that use registries as a platform for case records, data collection, randomization, and follow-up. Recently, the application of registry-based randomized controlled trials has attracted increasing attention in health research to address comparative effectiveness research questions in real-world settings, mainly due to their low cost, enhanced generalizability of findings, rapid consecutive enrollment, and the potential completeness of follow-up for the reference population, when compared with conventional randomized effectiveness trials. However several challenges of registry-based randomized controlled trials have to be taken into consideration, including registry data quality, ethical issues, and methodological challenges. In this article, we summarize the advantages, challenges, and areas for future research related to registry-based randomized controlled trials.


Epilepsia | 2014

Epilepsy surgery and meaningful improvements in quality of life: Results from a randomized controlled trial

Kirsten M. Fiest; Tolulope T. Sajobi; Samuel Wiebe

We examine improvement and worsening in quality of life (QOL) in terms of proportions achieving minimum clinically important change (MCID), and factors related to MCID, in patients with temporal lobe epilepsy randomized to medical or surgical treatment.


Frontiers in Psychology | 2010

Discriminant Analysis for Repeated Measures Data: A Review

Lisa M. Lix; Tolulope T. Sajobi

Discriminant analysis (DA) encompasses procedures for classifying observations into groups (i.e., predictive discriminative analysis) and describing the relative importance of variables for distinguishing amongst groups (i.e., descriptive discriminative analysis). In recent years, a number of developments have occurred in DA procedures for the analysis of data from repeated measures designs. Specifically, DA procedures have been developed for repeated measures data characterized by missing observations and/or unbalanced measurement occasions, as well as high-dimensional data in which measurements are collected repeatedly on two or more variables. This paper reviews the literature on DA procedures for univariate and multivariate repeated measures data, focusing on covariance pattern and linear mixed-effects models. A numeric example illustrates their implementation using SAS software.

Collaboration


Dive into the Tolulope T. Sajobi's collaboration.

Top Co-Authors

Avatar

Lisa M. Lix

University of Manitoba

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Richard Sawatzky

Trinity Western University

View shared research outputs
Researchain Logo
Decentralizing Knowledge